Tuesday, October 13, 2026

Back to today

From X

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

Deep Dive: Inter & Co

Inter & Co, Brazil’s second-largest neobank, grew over 20% with controlled delinquencies and 15% book-value compounding while trading at…

KHTRF · long

Knight Therapeutics INC

Knight Therapeutics (GUD-T) is a long position built on confidence in founder Jonathan Goodman, following his earlier success with Paladin…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 108

X accounts we follow

Every account on this site, hand-picked.

89 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.